Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
caffeine + warfarin + vitamin K + omeprazole + dextromethorphan + midazolam
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug cocktail is a research tool consisting of five cytochrome P450 (CYP450) probe substrates: caffeine (CYP1A2), warfarin (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A4). It was utilized by Hoffmann-La Roche in a Phase 1 clinical trial (NCT01001299) to assess the potential for vemurafenib (Zelboraf) to cause drug-drug interactions by inhibiting or inducing these specific metabolic enzymes in patients with metastatic melanoma. The cocktail allows for the simultaneous evaluation of multiple metabolic pathways by measuring the pharmacokinetics of each substrate in the presence and absence of the test drug. Vitamin K is typically included to mitigate the anticoagulant effects of warfarin during the study.
- Other names
- CYP450 probe cocktailCYP-450 probe cocktailCYP 450 probe cocktailRoche CYP450 cocktailFive-probe drug cocktail
02
Targets
VKORC1 (Vitamin K epoxide reductase complex subunit 1)
Beyond the preview
Go deeper on caffeine + warfarin + vitamin K + omeprazole + dextromethorphan + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on caffeine + warfarin + vitamin K + omeprazole + dextromethorphan + midazolam.